Key Points
- Vicki Sato, a Vir Biotechnology director, sold 22,000 shares on January 2 at an average price of $5.93 for $130,460, trimming her stake by 1.85% to 1,166,391 shares.
- Vir reported a quarterly loss of ($1.17) EPS"Moderate Buy" rating and a $17.30 average price target.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the business's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $5.93, for a total transaction of $130,460.00. Following the transaction, the director directly owned 1,166,391 shares of the company's stock, valued at $6,916,698.63. The trade was a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Vir Biotechnology Price Performance
Shares of VIR stock opened at $5.79 on Tuesday. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $14.45. The firm has a market capitalization of $805.50 million, a price-to-earnings ratio of -1.60 and a beta of 1.39. The business has a 50 day simple moving average of $5.98 and a 200 day simple moving average of $5.53.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.47). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. Vir Biotechnology's revenue for the quarter was up .8% on a year-over-year basis. During the same period last year, the business posted ($1.56) earnings per share. On average, equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.
Institutional Investors Weigh In On Vir Biotechnology
A number of institutional investors and hedge funds have recently modified their holdings of VIR. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at $35,000. FNY Investment Advisers LLC purchased a new position in shares of Vir Biotechnology in the third quarter worth approximately $38,000. Federated Hermes Inc. raised its holdings in shares of Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock valued at $46,000 after acquiring an additional 4,899 shares during the period. Apollon Wealth Management LLC purchased a new stake in shares of Vir Biotechnology in the 2nd quarter valued at approximately $50,000. Finally, Daiwa Securities Group Inc. boosted its stake in Vir Biotechnology by 2,200.6% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company's stock worth $62,000 after purchasing an additional 11,773 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on VIR shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $17.30.
View Our Latest Report on VIR
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
